At Novartis, we don’t just discover life-changing medicines, we're part of a broader effort to help ensure medicines reach the people who need them most, wherever they live, because the true value of ...
Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025 DTP offering to expand to other appropriate products; ...
Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer ...
Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPC NATALEE ...
DARe is currently investigating three fundamental processes associated with aging and age-related diseases that have potential to deliver novel therapeutic approaches. These processes are intricately ...
ノバルティス ファーマ株式会社（本社：東京都港区、代表取締役社長：ジョンポール・プリシーノ）（以下「ノバルティス ファーマ」）は、本日、「プルヴィクト ® 静注」（一般名 ...
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s ...
Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16, 2026, and will join the Executive ...
Rapid approvals in eight African countries now expected under a special global health scheme run by Swiss agency for therapeutic products (Swissmedic) Novartis plans to introduce infant-friendly ...
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities With new manufacturing capacity, Novartis will be able to produce 100% of its key ...
Having elevated levels of lipoprotein (a), or Lp (a) for short, increases a person’s chances of having a cardiovascular event such as a stroke or a heart attack. It was after having two heart attacks ...
Basel, March 19, 2025 – Novartis announced positive safety and efficacy results from the Phase III program for investigational intrathecal onasemnogene abeparvovec (OAV101 IT) in a broad population of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback